Tag: Eculizumab

1. In this randomized control trial of neuromyelitis optica spectrum disorder (NMOSD) patients with aquaporin-4 antibodies (AQP4-IgG), those randomized to receive the eculizumab complement inhibitor experienced a lower relapse rate over 24 months than placebo treated patients. 2. Eculizumab patients more commonly experienced upper respiratory tract infections (URI) and headaches. Evidence...
1. In this randomized control trial of neuromyelitis optica spectrum disorder (NMOSD) patients with aquaporin-4 antibodies (AQP4-IgG), those randomized to receive the eculizumab complement inhibitor experienced a lower relapse rate over 24 months than placebo treated patients. 2. Eculizumab patients more commonly experienced upper respiratory tract infections (URI) and headaches. Evidence...
Image: CC/Wiki/Uthman 1. Paroxysmal nocturnal hemoglobinuria (PNH) patients with poor response to eculizumab were found to have a mutation in complement protein C5.  2. When tested in vitro, the mutant C5 protein did not bind eculizumab, suggesting that the mechanism for resistance in these patients is protein-drug binding disruption caused by the...
June 1 – June 9, 2013 In this section, we will highlight the some of the high-impact studies, updates, and analyses published in medicine during the past week. Controlled Trial of Psychotherapy for Congolese Survivors of Sexual Violence In this cluster randomized control trial from the Democratic Republic of Congo, women subject...
Image: PD 1. Treatment with the anti-C5 monoclonal antibody eculizumab significantly improved hematologic markers and GFR in patients with atypical hemolytic uremic syndrome.  2. The improvements in hematologic markers and GFR were sustained beyond the duration of therapy.  Evidence Rating Level: 2 (Good)  Study Rundown: Atypical hemolytic-uremic syndrome (AHUS) is a genetic disease...